MLICM
APGE icon

Metropolitan Life Insurance Company (MetLife)’s Apogee Therapeutics APGE Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,185
Closed -$145K – 154
2024
Q1 		$145K Buy
2,185
+1,011
+86% +$44.1K 0.01% 858
2023
Q4 		$32.8K Hold
1,174
– – ﹤0.01% 1661
2023
Q3 		$25K Buy
+1,174
New +$25.9K ﹤0.01% 1784

Other funds holding APGE

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s APGE Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Apogee Therapeutics (APGE) in Q2 2024, closing a stake of 2,185 shares — an estimated $145K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in APGE in Q3 2023 and held it in 3 quarters. The position peaked at $145K in Q1 2024. 139 funds tracked by Wall St. Rank hold APGE as of Q2 2024.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Apogee Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 2,185 Apogee Therapeutics shares in Q2 2024, an estimated $145K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Apogee Therapeutics in Q3 2023 and held it in 3 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Apogee Therapeutics position peaked at $145K in Q1 2024.
  • 139 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.